Comunicati Stampa
Editoria e Media

Visiongain publishes Global Osteoporosis Pharmaceutical and Nutraceutical Market 2020-2030 report

Osteoporosis is a common disorder that is mostly common in the aging population and post- menopausal women. According to the International Osteoporosis Foundation, osteoporosis affects 1 in 4 women and more than 1 in 8 men over the age of 50 years, with 1 in 4 men and women having evidence of a vertebral fracture. The treatment and management of osteoporosis is a major challenge for healthcare workers and primary care givers. Numerous global and regional companies have been working on the R&D and production of various drugs and natural products called nutraceuticals for the treatment and management of osteoporosis. The Osteoporosis market was estimated to account for USD xyz bn in 2019 and is expected to grow with a CAGR of xyz% between 2020-2025.
LONDON, (informazione.news - comunicati stampa - editoria e media)

Osteoporosis is a common disorder that is mostly common in the aging population and post- menopausal women. According to the International Osteoporosis Foundation, osteoporosis affects 1 in 4 women and more than 1 in 8 men over the age of 50 years, with 1 in 4 men and women having evidence of a vertebral fracture. The treatment and management of osteoporosis is a major challenge for healthcare workers and primary care givers. Numerous global and regional companies have been working on the R&D and production of various drugs and natural products called nutraceuticals for the treatment and management of osteoporosis. The Osteoporosis market was estimated to account for USD xyz bn in 2019 and is expected to grow with a CAGR of xyz% between 2020-2025.

To access the data contained in this document please email contactus@visiongain.com

Visiongain's 338-page report that includes 160 tables and 134 figures throws light on the pharmaceutical and nutraceutical market, the current market trends, new product launches, market estimates of the major therapeutic drug like antiresorptive, anabolic and Others with its different types in both global and regional markets. We also focus on the major types of nutraceuticals like minerals, herbals and phytochemicals, dairy products and others that are being widely prescribed and consumed for the management of osteoporosis. The report also includes invaluable insights and into how the COVID-19 pandemic will affect the market in the forecast period.

The current report is a vision for an array of information from market valuation, market trends, a SWOT of the market, leading regional and global market players and other similar information. Some of the scope includes:

.

• Pharmaceuticals – It includes antiresorptive drugs which is further segmented into bisphosphonates, SERM, RLI, PH and Others. Major drugs like Fosamax, Boniva, Actonel, Aclasta, Evista, Duavee, Denosumab, Forteo, and many others are covered in the report. The anabolic drug like Evenity is also included in the report. Apart from them, drugs under clinical trials has also been covered in the report.

• Nutraceuticals – It includes the 4 major type of nutraceuticals like minerals, herbals and phytochemicals, dairy products and Others. The report covers 35 essential nutraceuticals like Calcium, Vitamins D, K, curcumin, embelin and others with global estimates forecast to 2030.

USA

Europe (UK, Germany , Italy , Spain and France )

• BRIC ( Brazil , India , Russia , China )

Japan

• Rest of the World

 

• Eli Lilly

• Amgen

• UCB

• GSK

• Merck and Co.

• Allergan

• Sanofi Aventis

• Pfizer

• Novartis

• Radius Health

• Zbiotics

• Kemin Europa

• Ajinomoto

• Herballife Nutrition

• Pharma Nord

 

 

 

 

 

Ajinomoto

Allergan

Amgen

Eli Lilly

GSK

Herballife Nutrition

Kemin Europa

Merck and Co.

Novartis

Pfizer

Pharma Nord

Radius Health

Sanofi Aventis

UCB

Zbiotics

 

 

Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili